Alirocumab after acute coronary syndrome in patients with a history of heart failure.
Harvey D WhiteGregory G SchwartzMichael SzarekDeepak L BhattVera A BittnerChern-En ChiangRafael DiazShaun G GoodmanJohan Wouter JukemaMegan LoyNeha PagidipatiRobert PordyArsen D RistićAndreas M ZeiherDaniel M WojdylaPhillippe Gabriel Stegnull nullPublished in: European heart journal (2022)
Alirocumab reduced MACE in patients without a history of HF but not in patients with a history of HF. Alirocumab did not reduce hospitalizations for HF in either group. Patients with a history of HF are a high-risk group that does not appear to benefit from PCSK9 inhibition after ACS.